GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (OTCPK:NOXOF) » Definitions » Investments And Advances

Noxopharm (Noxopharm) Investments And Advances : $0.50 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Noxopharm Investments And Advances?

Noxopharm's Investments And Advances for the quarter that ended in Dec. 2023 was $0.50 Mil.

Noxopharm's quarterly Investments And Advances declined from Dec. 2022 ($3.79 Mil) to Jun. 2023 ($0.65 Mil) and declined from Jun. 2023 ($0.65 Mil) to Dec. 2023 ($0.50 Mil).

Noxopharm's annual Investments And Advances declined from Jun. 2021 ($10.91 Mil) to Jun. 2022 ($3.81 Mil) and declined from Jun. 2022 ($3.81 Mil) to Jun. 2023 ($0.65 Mil).


Noxopharm Investments And Advances Historical Data

The historical data trend for Noxopharm's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Investments And Advances Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Investments And Advances
Get a 7-Day Free Trial - 4.51 10.91 3.81 0.65

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.45 3.81 3.79 0.65 0.50

Noxopharm Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Noxopharm (Noxopharm) Business Description

Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.